Women's interest in gene expression analysis for breast cancer recurrence risk

Journal of Clinical Oncology

Volumn 25, Issue 29, 2007, Pages 4628-4634

  O'Neill, Suzanne C ^a   Brewer, Noel T ^a   Lillie, Sarah E ^a   Morrill, Edward F ^a   Dees, E Claire ^a   Carey, Lisa A ^a   Rimer, Barbara K ^a  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RECURRENCE; CONTROLLED STUDY; DECISION MAKING; FEMALE; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENOMICS; HUMAN; MAJOR CLINICAL STUDY; PATIENT ATTITUDE; PATIENT PARTICIPATION; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT PLANNING;

ADULT; AGED; ATTITUDE TO HEALTH; BREAST NEOPLASMS; DECISION MAKING; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC COUNSELING; GENETIC SCREENING; GENOMICS; HUMANS; MIDDLE AGED; RECURRENCE; RISK;

EID: 35648995985     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.6255     Document Type: Article

References (46)

1. American Cancer Society: Cancer Facts and Figures. Atlanta, GA, American Cancer Society, 2007
2. Jemal A, Clegg LX, Ward E, et al: Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 101:3-27, 2004
3. Swain S: A step in the right direction. J Clin Oncol 24:3717-3718, 2006
4. Whelan T, Levine M, Willan A, et al: Effect of a decision aid on knowledge and treatment decision making for breast cancer surgery: A randomized trial. JAMA 292:435-441, 2004
5. Early Breast Cancer Trialists' Cooperative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
6. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer. Oxford, United Kingdom, Cochrane Library, 1, CD000486
7. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006
8. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
9. Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001
10. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418-8423, 2003
11. van't Veer L, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
12. Carey L, Perou CM, Livasy CA, et al: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502, 2006
13. Perreard L, Fan C, Quackenbush JF, et al: Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res 8:R23, 2006
14. Buchholz TA, Stivers DN, Stec J, et al: Global gene expression changes during neoadjuvant chemotherapy for human breast cancer. Cancer J 8:461-468, 2002
15. Sprarano J, Hayes D, Dees EC, et al: Phase III randomized study of adjuvant combination chemotherapy and hormonal therapy versus adjuvant hormonal therapy alone in women with previously resected axillary node-negative breast cancer with various levels of risk for recurrence. http://www.cancer.gov/ clinicaltrials/ECOG-PACCT-1
16. MINDACT Design and MINDACT overview. http://www.breastinternationalgroup. org/TransBIG/Mindact.aspx
17. Jansen S, Otten W, Stigglebout AM: Review of determinants of patients' preferences for adjuvant therapy in cancer. J Clin Oncol 22:3181-3190, 2004
18. Croyle RT, Lerman C: Interest in genetic testing for colon cancer susceptibility: Cognitive and emotional correlates. Prev Med 22:284-292, 1993
19. Smith KR, Croyle RT: Attitudes toward genetic testing for colon cancer risk. Am J Public Health 85:1435-1438, 1995
20. Lerman C, Daly M, Masny A, et al: Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol 12:843-850, 1994
21. Struewing J, Lerman C, Kase RG, et al: Anticipated uptake and impact of genetic testing in hereditary breast and ovarian-cancer families. Cancer Epidemiol Biomarkers Prev 4:169-173, 1995
22. Lillie SE, Brewer NT, O'Neill SC, et al: Retention and use of breast cancer recurrence risk information from genomic tests: The role of health literacy. Cancer Epidemiol Biomarkers Prev 16:249-255, 2007
23. Rimer BK, Halabi S, Skinner CS, et al: Effects of a mammography decision-making intervention at 12 and 24 months. Am J Prev Med 22:247-257, 2002
24. Olivotto IA, Bajdik CD, Ravdin PM, et al: Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23:2716-2725, 2005
25. Jacobsen PB, Valdimarsdottir HB, Brown KL, et al: Decision-making about genetic testing among women at familial risk for breast cancer. Psychosom Med 59:459-466, 1997
26. Degner L, Sloan JA, Venkatesh P: Control preferences scale. Can J Nurs Res 29:21-43, 1997
27. Bruera E, Sweeney C, Calder K, et al: Patients preferences versus physician perceptions of treatment decisions in cancer care. J Clin Oncol 19:2883-2885, 2001
28. Grunfeld E, Maher EJ, Browne S, et al: Advanced breast cancer patients' perceptions of decision making for palliative chemotherapy. J Clin Oncol 24:1090-1098, 2006
29. Harvard Pilgrim Healthcare: TA 6.35 Oncotype DX Recurrence Score Assay for Predicting Breast Cancer Recurrence. http://www.harvardpilgrim.org/portal/ page?_pageid=253,214340&_dad=portal&_schema=PORTAL#635
30. Genomic Health: Medicare Contractor Establishes Reimbursement Coverage Policy for Genomic Health's Oncotype DX Breast Cancer Test. http://investor. genomichealth.com/ReleaseDetail. cfm?ReleaseID=184309
31. Ravdin PM, Siminoff IA, Harvey JA: Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol 16:515-521, 1998
32. Duric VM, Stockler MR, Heritier S, et al: Patients' preferences for adjuvant chemotherapy in early breast cancer: What makes AC and CMF worthwhile now? Ann Oncol 16:1786-1794, 2005
33. Cioffi D: Asymmetry of doubt in medical self-diagnosis: The ambiguity of "uncertain wellness." J Pers Soc Psychol 61:969-980, 1991
34. Cioffi D: When good news is bad news: Medical wellness as a nonevent in undergraduates. Health Psychol 13:63-72, 1994
35. van Zuuren FJ, van Schie ECM, van Baaren NK: Uncertainty in the information provided during genetic counseling. Patient Educ Couns 32:129-139, 1997
36. Press NA, Yasui Y, Reynolds S, et al: Women's interest in genetic testing for breast cancer susceptibility may be based on unrealistic expectations. Am J Med Genet 99:99-110, 2001
37. Lloyd FJ, Reyna VF, Whalen P: Accuracy and ambiguity in counseling patients about genetic risk. Arch Intern Med 161:2411-2413, 2001
38. Peters E, McCaul KD, Stefanek M, et al: A heuristics approach to understanding cancer risk perception: Contributions from judgment and decision-making research. Ann Behav Med 31:45-52, 2066
39. Palda VA, Llewellyn-Thomas HA, Mackenzie RG, et al: A breast cancer patients' attitudes about rationing postlumpectomy radiation therapy: Applicability of trade-off methods to policy-making. J Clin Oncol 15:3192-3200, 1997
40. Chao C, Studts JL, Abell T, et al: Adjuvant chemotherapy for breast cancer: How presentation of recurrence risk influences decision-making. J Clin Oncol 21:4299-4305, 2003
41. Grunfeld EA, Ramirez AJ, Maher EJ, et al: Chemotherapy for advanced breast cancer: What influences oncologists' decision-making? Br J Cancer 84:1172-1178, 2001
42. US Preventive Services Task Force: Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility. Ann Intern Med 143:355-361, 2005
43. Ropka M, Wenzel J, Phillips EK, et al: Uptake rates for breast cancer genetic testing: A systematic review. Cancer Epidemiol Biomarkers Prev 15:840-855, 2006
44. Schlich-Bakker K, ten Kroode HFJ, Ausems MGEM: A literature review of the psychological impact of genetic testing on breast cancer patients. Patient Educ Couns 62:13-20, 2006
45. Jansen SJ, Otten W, Baas-Thijssen MC, et al: Explaining differences in attitude toward adjuvant chemotherapy between experienced and inexperienced breast cancer patients. J Clin Oncol 23:6623-6630, 2005
46. Jansen SJ, Otten W, van de Velde CJ, et al: The impact of the perception of treatment choice on satisfaction with treatment, experienced chemotherapy burden and current quality of life. Br J Cancer 91:56-61, 2004